Designing Evidence-Based Preventive Interventions That Reach More People, Faster, and with More Impact in Global Contexts.

Annu Rev Clin Psychol

Department of Psychiatry, University of California, Los Angeles, California 90024, USA; email:

Published: May 2021

This article demonstrates the substantial similarities globally among preventive, evidence-based interventions (EBIs) designed to address HIV by providing four examples: an HIV family-focused intervention, the Community Popular Opinion Leader intervention, a South African maternal/child health program, and an EBI for sex workers in India. Each identified the key problems in the target population, utilized well-established social cognitive theories, created processes for engaging the target population, set standards for staff accountability, and included routine data collection to facilitate iterative program improvements over time. Building EBIs based on these common, robust features is an alternative design strategy to replication with fidelity. These components provide a road map for researchers, especially those using new technologies, and for local providers seeking to deliver EBIs that match their clients' and communities' needs. Technology platforms and community organizations may serve as resources for designers of the next generation of EBIs, offering an alternative to repeatedly validating the same interventions and replicating them with fidelity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015738PMC
http://dx.doi.org/10.1146/annurev-clinpsy-081219-120453DOI Listing

Publication Analysis

Top Keywords

target population
8
designing evidence-based
4
evidence-based preventive
4
preventive interventions
4
interventions reach
4
reach people
4
people faster
4
faster impact
4
impact global
4
global contexts
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Actinogen Medical, Sydney, Australia.

Background: Selecting the optimal dose for clinical development is especially problematic for drugs directed at CNS-specific targets. For drugs with a novel mechanism of action, these problems are often greater. We describe Xanamem's clinical pharmacology, including the approach to dose selection and proof-of-concept studies.

View Article and Find Full Text PDF

Background: Understanding the fundamental differences between the human and pre-human brain is a prerequisite for designing meaningful models and therapies for AD. Expressed CHRFAM7A, a human restricted gene with carrier frequency of 75% in the human population predicts profound translational significance.

Method: The physiological role of CHRFAM7A in human brain is explored using multiomics approach on 600 post mortem human brain tissue samples (ROSMAP).

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Alzheon, Inc., Framingham, MA, USA.

Background: Oral ALZ-801 (valiltramiprosate), a brain-penetrant agent that inhibits amyloid-oligomer formation is being evaluated in a fully enrolled APOLLOE4 Phase 3 trial in APOE4/4 homozygotes with Early Alzheimer's disease (AD). ALZ-801 effects on plasma AD biomarkers were evaluated in a 104-week Phase 2 study in APOE4-carriers with CSF+ AD biomarkers. APOE4 is a major risk factor for amyloid-related imaging abnormalities (ARIA) in AD patients.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Stanford University School of Medicine, Stanford, CA, USA.

Recent advances in biomarkers, enabling the in vivo detection of pathological aggregates of alpha-synuclein (asyn), allow a shift from a clinical to a biological definition of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). The newly proposed "Neuronal alpha-Synuclein Disease (NSD)" is defined by the presence of pathologic neuronal (n-asyn) species detected in vivo (S), irrespective of any specific clinical syndrome. Additional biological anchors include dopaminergic neuronal dysfunction (D).

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

National Hospital for Neurology and Neurosurgery, University College London, London, London, United Kingdom.

Anti-amyloid therapies are ideal candidates for prevention trials. Secondary prevention in those at risk of ADAD (DIAN-TU) has shown reduction of brain amyloid deposition leads to significant downstream biological change; early secondary prevention using a monoclonal antibody in sporadic AD (AHEAD 3-45) is ongoing and will provide critical information on whether treating earlier leads to greater clinical benefit. However, this is not preventing disease but delaying onset in those with presymptomatic disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!